These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 19347829)
1. P63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples: implications in treatment selection. Jorda M; Gomez-Fernandez C; Garcia M; Mousavi F; Walker G; Mejias A; Fernandez-Castro G; Ganjei-Azar P Cancer; 2009 Feb; 117(1):46-50. PubMed ID: 19347829 [TBL] [Abstract][Full Text] [Related]
2. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Mukhopadhyay S; Katzenstein AL Am J Surg Pathol; 2011 Jan; 35(1):15-25. PubMed ID: 21164283 [TBL] [Abstract][Full Text] [Related]
3. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Camilo R; Capelozzi VL; Siqueira SA; Del Carlo Bernardi F Hum Pathol; 2006 May; 37(5):542-6. PubMed ID: 16647951 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the expression levels of napsin A, thyroid transcription factor-1, and p63 in nonsmall cell lung cancer using cytocentrifuged bronchial brushings. Aikawa E; Kawahara A; Hattori S; Yamaguchi T; Abe H; Taira T; Azuma K; Kage M Cancer Cytopathol; 2011 Oct; 119(5):335-45. PubMed ID: 21717589 [TBL] [Abstract][Full Text] [Related]
5. Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. Pirinen R; Leinonen T; Böhm J; Johansson R; Ropponen K; Kumpulainen E; Kosma VM Hum Pathol; 2005 Jan; 36(1):44-50. PubMed ID: 15712181 [TBL] [Abstract][Full Text] [Related]
6. Utilization of p40 (ΔNp63) with p63 and cytokeratin 5/6 immunohistochemistry in non-small cell lung carcinoma fine-needle aspiration biopsy. Collins BT; Wang JF; Bernadt CT Acta Cytol; 2013; 57(6):619-24. PubMed ID: 24107322 [TBL] [Abstract][Full Text] [Related]
7. Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. Lyda MH; Weiss LM Hum Pathol; 2000 Aug; 31(8):980-7. PubMed ID: 10987260 [TBL] [Abstract][Full Text] [Related]
8. The expression of Bcl-2 family proteins differs between nonsmall cell lung carcinoma subtypes. Berrieman HK; Smith L; O'Kane SL; Campbell A; Lind MJ; Cawkwell L Cancer; 2005 Apr; 103(7):1415-9. PubMed ID: 15700269 [TBL] [Abstract][Full Text] [Related]
9. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Hastürk S; Kemp B; Kalapurakal SK; Kurie JM; Hong WK; Lee JS Cancer; 2002 Feb; 94(4):1023-31. PubMed ID: 11920472 [TBL] [Abstract][Full Text] [Related]
10. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Khayyata S; Yun S; Pasha T; Jian B; McGrath C; Yu G; Gupta P; Baloch Z Diagn Cytopathol; 2009 Mar; 37(3):178-83. PubMed ID: 19170169 [TBL] [Abstract][Full Text] [Related]
11. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Massion PP; Taflan PM; Jamshedur Rahman SM; Yildiz P; Shyr Y; Edgerton ME; Westfall MD; Roberts JR; Pietenpol JA; Carbone DP; Gonzalez AL Cancer Res; 2003 Nov; 63(21):7113-21. PubMed ID: 14612504 [TBL] [Abstract][Full Text] [Related]
12. A reevaluation of the clinical significance of histological subtyping of non--small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Rossi G; Pelosi G; Graziano P; Barbareschi M; Papotti M Int J Surg Pathol; 2009 Jun; 17(3):206-18. PubMed ID: 19443885 [TBL] [Abstract][Full Text] [Related]
13. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma. Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263 [TBL] [Abstract][Full Text] [Related]
14. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553 [TBL] [Abstract][Full Text] [Related]
15. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? Pelosi G; Pasini F; Olsen Stenholm C; Pastorino U; Maisonneuve P; Sonzogni A; Maffini F; Pruneri G; Fraggetta F; Cavallon A; Roz E; Iannucci A; Bresaola E; Viale G J Pathol; 2002 Sep; 198(1):100-9. PubMed ID: 12210069 [TBL] [Abstract][Full Text] [Related]
16. The use of p63 as an effective immunomarker in the diagnosis of pulmonary squamous cell carcinomas on de-stained bronchial lavage cytological smears. Uke M; Rekhi B; Ajit D; Jambhekar NA Cytopathology; 2010 Feb; 21(1):56-63. PubMed ID: 19744186 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Soltermann A; Tischler V; Arbogast S; Braun J; Probst-Hensch N; Weder W; Moch H; Kristiansen G Clin Cancer Res; 2008 Nov; 14(22):7430-7. PubMed ID: 19010860 [TBL] [Abstract][Full Text] [Related]
19. Combined large cell neuroendocrine, small cell and squamous carcinomas of the lung with rhabdoid cells. Chetty R Pathology; 2000 Aug; 32(3):209-12. PubMed ID: 10968398 [TBL] [Abstract][Full Text] [Related]